A Neutral Risk on the Development of New-Onset Diabetes Mellitus (NODM) in Taiwanese Patients with Dyslipidaemia Treated with Fibrates

Table 1

Descriptive characteristics of fibrate prescriptions in the population, 2005–2010.

Characteristics	NODM		No-NODM		Total		𝑃-value
	𝑛	%	𝑛	%	𝑛	%
Total	145	3.8	3,670	96.2	3,815	100
Age (year, mean ± SD)	56.10±12.21		55.57±12.56		55.59±12.54		0.616
Gender
Female	58	40.00	1,372	37.38	1,430	37.48	0.523
Male	87	60.00	2,298	62.62	2,385	62.52
Drug group
Fenofibrate	104	71.72	2,702	73.62	2,806	73.55	0.611
Gemfibrozil	41	28.28	968	26.38	1,009	26.45
Mean dose
Fenofibrate	262.17±238.50		222.03±152.52		223.52±156.67		0.048
Gemfibrozil	703.90±328.46		637.44±323.34		640.14±323.65		0.198

Differences in continuous variables were analysed using the unpaired student’s t-test.
Categorical variables were analysed using by either Fisher’s exact test or the chi-squared test.